Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert)

Retina

Volumn 32, Issue 3, 2012, Pages 537-542

  Patel, Chirag C ^a   Mandava, Naresh ^a   Oliver, Scott C N ^a   Braverman, Rebecca ^a   Quiroz Mercado, Hugo ^a   Olson, Jeffrey L ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINOLONE ACETONIDE; PROLINE; STEROID;

ADOLESCENT; ARTICLE; CASE REPORT; CATARACT EXTRACTION; CHILD; CILIARY DISK; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; IMPLANT; INTRACTABLE NONINFECTIOUS POSTERIOR UVEITIS; INTRAOCULAR PRESSURE; LENSECTOMY; MALE; PEDIATRICS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PSEUDOPHAKIA; SCHOOL CHILD; SURGICAL TECHNIQUE; SUTURE; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; HUMANS; INTRAOCULAR PRESSURE; MALE; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; UVEITIS, POSTERIOR; VISUAL ACUITY; VITREOUS BODY;

EID: 84858073408     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31822058bb     Document Type: Article

References (13)

1. Castellarin A, Pieramici DJ. Anterior segment complications following periocular and intraocular injections. Ophthalmol Clin North Am 2004;17:583-590. (Pubitemid 39472696)
2. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33-35.
3. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular and systemic corticosteroids. Curr Opin Ophthalmol 2000;11:478-483.
4. Moshfeghi DM, Lowder CY, Roth DB, Kaiser PK. Retinal and choroidal vascular occlusion after posterior sub-Tenon triamcinolone injection. Am J Ophthalmol 2002;134:132-134. (Pubitemid 34722728)
5. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004; 24:676-698. (Pubitemid 39391758)
6. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-796. (Pubitemid 37330020)
7. Lester RS, Knowles SR, Shear NH. The risks of systemic corticosteroid use. Dermatol Clin 1998;16:277-288.
8. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513.
9. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-3575.
10. Callanan DJ, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant three-year clinical trial results. Arch Ophthalmol 2008;126:1191-2001.
11. Taban M, Lowder CY, Kaiser PK. Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis. Retina 2008;28:1280-1288.
12. Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis associated uveitis. Curr Opin Ophthalmol 2003;14: 395-398. (Pubitemid 38333579)
13. Cassidy JT, Levinson JE, Bass JC, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 1986;29:274-281. (Pubitemid 17022828)